ArticleProceedings of the National Academy of Sciences of the United States of America2004
Translationally controlled tumor protein is a target of tumor reversion.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 239 citations in OpenAlex.
- Pharmacological Modulators of TCTP: Opportunities and Challenges for Drug Repurposing.International journal of molecular sciences · 2026Review
- Repurposing the Antidepressant Sertraline: A Systematic Scoping Review of Its Anticancer Mechanisms.Pharmacology research & perspectives · 2025Article
- Rhodosporidium toruloides-a new surrogate model to study rapamycin induced effects on human aging and cancer.Cellular and molecular life sciences : CMLS · 2025Article
- Translationally controlled tumor protein interacts with connexin 43 and facilitates intercellular coupling between cardiomyocytes.Frontiers in cell and developmental biology · 2025Article
- The multifaceted potential ofHeliyon · 2024Review
- TCTP regulates genotoxic stress and tumorigenicity via intercellular vesicular signaling.EMBO reports · 2024Article
- The phenotypic reversion of cancer: Experimental evidences on cancer reversibility through epigenetic mechanisms (Review).Oncology reports · 2024Review
- UsingCells · 2023Review
- Prognostic value of translationally controlled tumor protein in colon cancer.Molecular and clinical oncology · 2023Article
- Normalizing Input-Output Relationships of Cancer Networks for Reversion Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Harnessing the value of TCTP in breast cancer treatment resistance: an opportunity for personalized therapy.Cancer drug resistance (Alhambra, Calif.) · 2023Review
- Antidepressant Drug Sertraline against Human Cancer Cells.Biomolecules · 2022Review
- Translationally controlled tumor protein: the mediator promoting cancer invasion and migration and its potential clinical prospects.Journal of Zhejiang University. Science. B · 2022Review
- Tctp regulates the level and localization of Foxo for cell growth in Drosophila.Cell death discovery · 2022Article
- SUMOylation of Translationally Regulated Tumor Protein Modulates Its Immune Function.Frontiers in immunology · 2022Article
- TCTP protein degradation by targeting mTORC1 and signaling through S6K, Akt, and Plk1 sensitizes lung cancer cells to DNA-damaging drugs.Scientific reports · 2021Article
- Topoisomerase II is regulated by translationally controlled tumor protein for cell survival during organ growth in Drosophila.Cell death & disease · 2021Article
- A novel ligand of the translationally controlled tumor protein (TCTP) identified by virtual drug screening for cancer differentiation therapy.Investigational new drugs · 2021Article
- Diversity roles of CHD1L in normal cell function and tumorigenesis.Biomarker research · 2021Review
- Allergic Inflammation Caused by Dimerized Translationally Controlled Tumor Protein is Attenuated by Cardamonin.Frontiers in pharmacology · 2021Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
By analyzing the gene expression profile between tumor cells and revertant counterparts that have a suppressed malignant phenotype, we previously reported a significant down-regulation of translationally controlled tumor protein (TCTP) in the revertants. In the present study, we derived, by using the H1 parvovirus as a selective agent, revertants from three major solid cancers: colon, lung, and melanoma cell lines. These cells have a strongly suppressed malignant phenotype both in vitro and in vivo. The level of TCTP is decreased in most of the revertants. To verify whether inhibition of TCTP expression induces changes in the malignant phenotype, in the classical, well established model of "flat reversion," v-src-transformed NIH3T3 cells were transfected with antisense TCTP. By inhibiting the expression of TCTP, the number of revertant cells was raised to 30%, instead of the reported rate for spontaneous flat revertants of 10(-6). Because TCTP encodes for a histamine-releasing factor, we tested the hypothesis that inhibitors of the histaminic pathway could be effective against tumor cells. We show that some antihistaminic compounds (hydroxyzine and promethazine) and other pharmacological compounds with a related structure (including thioridazine and sertraline) kill tumor cells and significantly decrease the level of TCTP. All together, these data suggest that, with tumor reversion used as a working model, TCTP was identified as a target and drugs were selected that decrease its expression and kill tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.